Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

Lignende værker

• Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer
  af: Erselcan, T, et al.
  Udgivet: (2000)
• The leucocyte nadir, a predictor of chemotherapy efficacy?
  af: Kvinnsland, S
  Udgivet: (1999)
• Adjuvant oophorectomy versus CMF for premenopausal, node-positive, hormone receptor positive patients.
  af: Bethune, W. A.
  Udgivet: (1991)
• A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
  af: De Placido, S, et al.
  Udgivet: (2005)
• Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.
  af: Saarto, T., et al.
  Udgivet: (1997)